More globally, the increased risk of CHM in NF-NS, regardless of the type of NF1 pathogenic variant, appears to be confirmed by pooled data from the literature, with a significantly increased frequency of CHM and PVS at 36.8% and 24.3%, respectively. This evidence concerns the gene NF1 and neurofibromatosis-Noonan syndrome.